Research programme: PPAR agonists - DARA Biosciences

Drug Profile

Research programme: PPAR agonists - DARA Biosciences

Alternative Names: DB900 series; Peroxisome proliferator activated receptor agonists; PPAR agonists - DARA

Latest Information Update: 17 Feb 2012

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer DARA BioSciences
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Feb 2012 Research programme: PPAR agonists - DARA Biosciences is available for licensing as of 15 Feb 2012. http://www.darabio.com
  • 30 Mar 2010 Suspended - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top